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Protocol
AbstrACt
Introduction The ‘Engager’ programme is a ‘through-
the-gate’ intervention designed to support prisoners with 
common mental health problems as they transition from 
prison back into the community. The trial will evaluate the 
clinical and cost-effectiveness of the Engager intervention.
Methods and analysis The study is a parallel two-group 
randomised controlled trial with 1:1 individual allocation 
to either: (a) the Engager intervention plus standard care 
(intervention group) or (b) standard care alone (control 
group) across two investigation centres (South West 
and North West of England). Two hundred and eighty 
prisoners meeting eligibility criteria will take part. Engager 
is a person-centred complex intervention delivered by 
practitioners and aimed at addressing offenders’ mental 
health and social care needs. It comprises one-to-one 
support for participants prior to release from prison and 
for up to 20 weeks postrelease. The primary outcome is 
change in psychological distress measured by the Clinical 
Outcomes in Routine Evaluation-Outcome Measure at 
6 months postrelease. Secondary outcomes include: 
assessment of subjective met/unmet need, drug and 
alcohol use, health-related quality of life and well-being-
related quality of life measured at 3, 6 and 12 months 
postrelease; change in objective social domains, drug 
and alcohol dependence, service utilisation and perceived 
helpfulness of services and change in psychological 
constructs related to desistence at 6 and 12 months 
postrelease; and recidivism at 12 months postrelease. 
A process evaluation will assess fidelity of intervention 
delivery, test hypothesised mechanisms of action and look 
for unintended consequences. An economic evaluation will 
estimate the cost-effectiveness.
Ethics and dissemination This study has been approved 
by the Wales Research Ethics Committee 3 (ref: 15/
WA/0314) and the National Offender Management 
Service (ref: 2015–283). Findings will be disseminated to 
commissioners, clinicians and service users via papers 
and presentations.
trial registration number ISRCTN11707331; Pre-results.
IntroduCtIon
This paper presents the protocol for a 
randomised control trial (RCT) to test the 
effectiveness of a complex ‘through-the-gate’ 
intervention for prisoners with common 
mental health problems. RCTs in prison 
settings are rare,1 and we are unaware of any 
that have focused on responses to common 
mental health problems. This is a surprising 
omission, given that the point prevalence 
of mental health problems among prison 
populations has been reported as between 
50% and 90% both in the UK2–4 and inter-
nationally.5 In England and Wales, an Office 
of National Statistics survey reported high 
strengths and limitations of this study
 ► The study will be a two-centre, randomised 
controlled trial of a through-the-gate intervention for 
prisoners with common mental health problems; it 
will provide much-needed evidence of what works 
for this difficult-to-engage population.
 ► The primary and secondary outcomes have been 
selected following extensive piloting work and cover 
a broad range of outcome domains that could be 
impacted by the complex intervention.
 ► The study adopts a flexible and pragmatic approach 
to data collection to try to overcome the challenges 
of following up this population after release from 
prison.
 ► The lack of blinding of researchers collecting study 
data is a limitation of the study design.
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rates of personality disorder (64%), neurotic disorders 
(40%), drug dependency (43%) and hazardous alcohol 
use (63%) in sentenced prisoners, with higher rates 
generally being found in remand prisoners.6 High levels 
of suicide, suicidal thoughts and self-harming behaviour 
have also been reported among both prisoners and 
ex-prisoners,7 with the risk of suicide for male offenders 
leaving prison being eight times the national average.8 9 
Our development work indicated high rates of anxiety 
and depression, with 47% reaching likely caseness for 
anxiety, post-traumatic stress disorder (PTSD) or depres-
sion while in prison, of which 32% were still ‘cases’ after 
release. There was also substantial co-morbidity, especially 
with substance abuse.10 
In addition to mental health problems, offenders have 
wide-ranging personal and social problems, including 
homelessness, unemployment and broken relationships 
with both partners and children, and they typically live 
chaotic lives. In our previous cross-sectional study of 
200 offenders (100 serving prison sentences and 100 
serving community sentences), 37% reported problems 
with family relationships; the majority of the sample 
were unemployed or on long-term sickness benefit 
(65% in prison and 70% in the community sample), 
and 26% had ongoing legal or criminal justice issues.11 
These results echo previous surveys of prisoners.12–15 
The Surveying Prisoner Crime Reduction study, which 
is based on regular interviews with a cohort of prisoners 
in England and Wales before and after release, shows 
two-thirds reporting unemployed status before going into 
custody and 37% reporting the need for assistance in 
finding accommodation on release.16 These issues tend 
to be the focus of offenders’ own concerns, indicating a 
crucial need to address them, as well as providing moti-
vation for change. The international literature identifies 
similar constellations of inter-related personal and social 
problems among numerous prisoners leaving custody 
and similar challenges facing resettlement (or ‘re-entry’) 
services.17–21
The cost of failing to address these issues is high. Those 
serving short-term sentences place a considerable burden 
on society. Twelve-month proven reoffending rates for 
short-sentence prisoners are currently close to 60%,22 and 
in addition to the distress and inconvenience commonly 
experienced by their victims, many ‘volume’ offences 
have a surprisingly high financial impact. For example, 
in 2010, the costs of an average domestic burglary were 
estimated at £3925 and of a less serious wounding at 
£9790.23 Therefore, the potential benefits of addressing 
these issues, to individuals and communities, as well the 
financial savings, are significant.
There are complex relationships between mental 
health, substance misuse, social exclusion and criminal 
behaviour. However, these tend to be studied separately, 
with interventions designed to address them being devel-
oped and delivered in isolation. An underpinning aim 
of the Engager intervention is to identify and overcome 
service barriers, particularly between health and criminal 
justice sectors, and embed multi-agency working within 
the intervention.
In the UK, prison healthcare is often provided by a 
number of different National Health Service (NHS), 
private, or third-sector organisations, each providing sepa-
rate primary care, mental healthcare, drug and alcohol 
services. Opiate substitution services are now generally 
available in prison, and mechanisms for achieving conti-
nuity postrelease are improving. Mental health services 
for those with severe and enduring mental illness have 
faced considerable challenges24 but have improved 
care for those with psychosis, with new evidence now 
supporting the development of mental health pathways 
on release.25
By contrast, provision of psychological therapy for 
offenders with common mental health problems is 
limited in both prison and community settings.11 The 
prison environment complicates diagnostic assess-
ment,4 and for some, fewer stressors in prison may 
reduce anxiety, making it difficult to identify mental 
health problems that may arise postrelease. The focus 
of hard-pressed prison healthcare staff is on imme-
diate concerns, rather than longer-term postrelease 
planning. Improving Access to Psychological Therapies 
(IAPT) services in prisons are still in the early stages of 
development.
Once released into the community, ex-prisoners with 
common mental health problems are, in theory, provided 
for by mainstream statutory services including general 
practice, community mental health teams and IAPT 
services. In reality, few access these services. For example, 
in a previous study, we found an average of only 0.96 
contacts with mental health services per offender per year 
for those reporting common mental health problems,11 
suggesting that a lack of care on release is the norm.26 27
Despite negligible uptake and high need, no systems 
worldwide have been identified for actively engaging 
offenders with common mental health problems while in 
prison, providing initial treatment and transferring care 
to community teams. Many ex-prisoners, like others with 
common mental health problems complicated by co-mor-
bidity, fall between primary care, IAPT and specialist 
services.28–31 They are further disadvantaged by their 
reluctance both to seek help and to accept mental health 
diagnoses and by lower levels of general practitioner 
registration.10 11 26 Services can also be seen as resistant 
to offenders and are not designed to meet the needs of 
those with complex and multiple vulnerabilities.32 This 
contrasts with well-established services, together with 
arrangements for transfer of care, for those with opiate 
misuse.33 34 In a relatively small proportion of cases, 
psychological input and/or general support is provided 
by statutory or third-sector resettlement services, from 
probation-delivered thinking skills ‘booster’ programmes 
for prisoners on licence, through to volunteer or 
peer-mentoring services,35 36 although currently resettle-
ment plans typically contain limited reference to health 
concerns.
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In view of these factors, provision of care for common 
mental health problems should be considered as part of 
the range of services making up collaborative care and 
directed towards improving social outcomes and resettle-
ment. The Engager research programme was designed to 
develop and evaluate a collaborative care intervention for 
prisoners with common mental health problems, near to 
and after release from prison, supporting multiple needs 
rather than focused on specific diagnoses or on a partic-
ular therapy. We describe the methods of the Engager 
trial here.
Aims and hypothesis
The Engager trial aims to answer the research question: 
What is the effectiveness and cost-effectiveness of the Engager 
intervention plus usual care, compared with usual care alone, 
in prisoners with common mental health problems, both before 
release and for between 3 and 5 months following release from 
prison? The primary hypothesis is that the participants 
receiving the Engager intervention plus usual care (the 
‘intervention group’) will have reduced levels of psycho-
logical distress as measured by the Clinical Outcomes in 
Routine Evaluation-Outcome Measure (CORE-OM)37 
at 6 months postrelease from prison (primary outcome) 
compared with participants receiving usual care alone 
(the ‘control group’).
Secondary hypotheses of the trial are that, compared 
with the control group, the intervention group will have:
 ► an increase in the number of self-reported met needs 
in relation to accommodation, education, work/
money/benefits, family/friends/company/intimacy, 
physical and mental health, safety to self and self-care, 
safety to others and leisure activities;
 ► improvements in social outcomes (accommodation, 
education, employment and benefits);
 ► a decrease in self-reported substance use and level of 
dependence;
 ► positive changes in service use across health, criminal 
justice, social care and third-sector organisations;
 ► improvements in psychological constructs related to 
well-being and desistence;
 ► improvement in health-related quality of life, well-be-
ing-related quality of life, subjective experience of 
care received and perceived helpfulness of services;
 ► a reduction in levels of proven reoffending.
The trial will estimate the total cost and per prisoner 
cost of providing the Engager intervention and the 
cost-effectiveness of the Engager intervention plus usual 
care versus usual care alone across health, social care and 
criminal justice sectors.
The trial also includes a parallel process evaluation, 
designed to: determine the degree to which the core 
mechanisms of the intervention were delivered; eval-
uate the extent to which the core mechanisms of the 
intervention produced the intended outcomes; identify 
aspects of the intervention and delivery that could be 
improved; and explore unintended consequences of the 
intervention.
MEthods And AnAlysIs
design
The study is a parallel two-group randomised controlled 
trial (RCT) with 1:1 individual participant allocation 
to either the Engager intervention plus standard care 
(intervention group) or standard care alone (control 
group), with economic evaluation and parallel process 
evaluation. The trial is registered as ISRCTN11707331 
(4 February  2016).
setting
The study will be conducted in two investigation centres 
(South West and North West of England). Participants 
will be recruited from three prisons, two in the South 
West and one in the North West of England. Participants 
will be recruited in equal numbers from each of the 
two investigation centres, for both the intervention and 
control groups. Recruitment and baseline interviews will 
take place in the prisons, with follow-up interviews taking 
place in a suitable community location or (for those who 
are back in prison) in prison. Conduct of the trial in 
each centre will be led by a local principal investigator, 
supported by a research team, all of whom have received 
training in Good Clinical Practice (GCP) and the require-
ments of the study protocol.
study population
Potential participants will be men serving a custodial 
sentence of 2 years or less, who are within 4–20 weeks 
from release from prison and who are being released to 
the geographical area of the study. Potential participants 
will be identified using the Prison National Offender 
Management Information System. Female prisoners, men 
on remand and those with a diagnosis of serious mental 
illness or on the Offender Personality Disorder Pathway 
will be excluded from the trial. The full list of participant 
inclusion and exclusion criteria is provided in box. 
Individuals will be approached up to 20 weeks prior to 
release. Initial contact will be made by a member of the 
research team. They will be given the Participant Informa-
tion Sheet (online supplementary appendix 1, informa-
tion sheet for RCT V5 14.03.17), and the researcher will 
discuss any queries/concerns with them. Researchers will 
take consent (online supplementary appendix 2, consent 
form for RCT V5 24.03.2017) from individuals who wish 
to participate. All individuals providing written informed 
consent will complete a short screening interview to iden-
tify those currently experiencing common mental health 
problems or who have experienced common mental 
health problems in the previous 2 years that impacted on 
their day-to-day functioning and are likely to experience 
similar problems on release. The screening interview 
comprises the Patient Health Questionnaire-9 (PHQ-
9),38 the Generalised Anxiety Disorder-7 (GAD-7),39 the 
Primary Care PTSD Screen (PC-PTSD)40 and a bespoke 
Historical Common Mental Health Problem screen. The 
PHQ-9, GAD-7 and PC-PTSD are routinely used in IAPT 
services and are quick and easy-to-administer screening 
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tools for depression, anxiety and PTSD, respectively. The 
researcher will read the questions to the participants, 
using a narrative conversational format developed in 
our pilot work to facilitate engagement.41 Individuals will 
be considered suitable for inclusion in the study if the 
screening interview indicates that they:
 ► have a current common mental health problem as 
indicated by a score of 10 or more on the PHQ-9 or 
GAD-7, or 3 or more on the PC-PTSD; or
 ► have experienced a common mental health problem 
during the past 2 years, which prevented them from 
functioning normally in everyday tasks and which is 
likely to be a problem for them again following their 
release.i
If a participant screens in following this assessment, 
they will continue to the full baseline interview.
Participants will be informed that participation is 
voluntary and that they are free to withdraw from the 
study at any time, and it is stressed that withdrawal from 
the study will not affect their legal rights. They will also be 
informed that the researcher has a duty to inform prison 
i Participants will be directly asked whether they had periods of 2 weeks 
or more in the 2 years before coming into prison when they experi-
enced a problem (eg, stress), whether this affected them functioning 
normally in everyday tasks and whether they think this will be a problem 
again once they have been released. These three questions were then 
repeated for problems involving feeling down or depressed, feeling 
anxious or worrying a lot, having nightmares or horrible thoughts or 
having panic attacks. If the participants respond yes to all three ques-
tions for any of the five types of problems and could provide an example 
of how it affected their functioning, then they met this inclusion criteria 
for the study.
staff if they disclose certain information, such as intent to 
harm self or others.
randomisation
Participants will be individually randomised in a 1:1 ratio 
to receive either the Engager intervention in addition 
to usual care, or usual care alone. Randomisation will 
be achieved by means of a web-based system created by 
Peninsula Clinical Trials Unit (PenCTU). Randomisation 
numbers will be computer generated and assigned in 
strict sequence. Randomisation will be stratified to ensure 
balance between the two treatment arms across the two 
investigator centres, with each centre having an indepen-
dent sequence list for an equal number of participants. At 
the point of randomisation, participants will be assigned 
the next randomisation number in the sequence.
Confirmation that randomisation has been performed 
will be communicated in an unblinded fashion to the 
investigator site staff and to key members of the central 
research team, via emails automatically generated by the 
randomisation website. A researcher (usually the same 
researcher who conducted the baseline interview) will 
visit the participant in prison to deliver a letter informing 
the participant of the randomisation outcome. The 
researcher will go through the letter with the partici-
pant, ensuring that they understand their grouping and 
when they will be seen next and by whom (researcher or 
practitioner).
Intervention
The intervention is designed to engage with individuals 
with common mental health problems who are close to 
release, developing a pathway of care in preparation for 
release and resettlement in the community. The interven-
tion will be delivered in prison between 4 and 16 weeks 
prerelease and for up to 20 weeks postrelease. Providing 
they are still willing to engage, all participants will receive 
the intervention for 8 weeks postrelease. However, for 
those who need further support, the intervention can 
continue for an additional 12 weeks, although at a lower 
intensity. This flexible approach to the length of the 
intervention followed on from our pilot work, which indi-
cated that, while for many participants 2–3 months was 
sufficient, others required support from the practitioner 
for a longer period.
Engager is a manualised, person-centred interven-
tion aiming to address mental health needs as well as to 
support wider issues such as accommodation, education, 
social relationships and money management. It was devel-
oped by bringing together evidence from a realist review,42 
focus groups, case studies and a formative process evalua-
tion. It will be delivered by experienced support workers 
and supervisor team leaders with experience of therapy. A 
mentalisation-informed approach underpins all elements 
of the intervention. Use of existing practitioner skills 
(eg, those used in coaching, solution-focused therapy, 
behavioural activation, cognitive–behavioural therapy) is 
also key to intervention delivery.
box trial entry criteria
Inclusion criteria
 ► Men with prison sentences of up to and including 2 years.
 ► Being released to the geographical area of the study.
 ► Having between 4 and 20 weeks remaining to serve in prison.
 ► Willing to engage with treatment services and research procedures.
 ► Identified using screening instruments as having, or likely to have 
following release, common mental health problems.
Exclusion criteria
 ► Men on remand.
 ► Women (numbers are smaller, and prisons are remote; resettlement 
needs are different; research procedures developed are not feasible 
for this context). Research will be in male prisons only.
 ► Those with serious and enduring mental disorder and/or on the 
caseload of the prison in-reach team.
 ► Those with active suicidal intent requiring management under 
the safer custody process or prison in-reach team and where the 
healthcare team managing the prisoner feels it would be detrimental. 
Once risk levels reduce individuals in this group will be eligible if not 
excluded for another reason.
 ► Those with primary personality disorder who are on the caseload of 
the Offender Personality Disorder Pathway programme.
 ► Those who present a serious risk of harm to the researchers or 
intervention practitioners.
 ► Those unable to provide informed consent.
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At prerelease stage, practitioner and participant will 
develop a shared understanding of the participant’s 
needs and goals, recognising the links between emotion, 
thinking, behaviour and social outcomes. A goal attain-
ment plan will be developed and followed, including 
liaison with relevant agencies and the participant’s social 
networks. Engagement will be maintained throughout 
the prerelease period; when required, all-day support will 
be given on release day.
Following release, the practitioner will provide support 
for the participant to re-enter the community and engage 
with services. They will continue to work with the partici-
pant and any relevant organisations to help them achieve 
their goals, while encouraging the participant to take 
responsibility for self-care. The practitioner will also 
prepare the participant for the end of the intervention, 
while liaising with relevant community organisations 
regarding continuity of care.
Control group
Individuals in the control group will receive care as 
usual. In prison, they will be able to access primary 
care, mental health and substance misuse services, as 
would usually occur. They will also receive support from 
criminal justice and any other third-sector organisa-
tions as standard. Their use of health, criminal justice 
and third-sector services will be recorded by means of 
an adapted Client Service Receipt Inventory (CSRI), 
and medication usage will also be collected from prison 
medical records and via participant self-report in the 
community.
Contamination
There is unlikely to be significant contamination between 
the intervention and control arms of the study, although it 
is theoretically possible for: trainers to train practitioners 
elsewhere, practitioners to pass on skills and working 
practices to those treating control individuals, interven-
tion materials to influence practice for control individ-
uals and offenders to influence each other. However, the 
risk of contamination is considered low primarily because 
there is no alternative funded pathway for delivery of the 
substantive components of the intervention for those in 
the control arm. Engager practitioners form a separate 
team in prison and while other practitioners are informed 
about the intervention, (1) they are not trained in the 
detail, (2) they tend not to have contact with our partic-
ipants who are selected for the study using case finding 
and (3) they don’t have governance arrangements in 
place to follow individuals into the community. Cluster 
randomisation to prevent contamination would have 
been theoretically possible by randomising at a prison 
level, but practically not feasible because prisons are clus-
tered together in localities, with one for new entrants, so 
each cluster would have several prisons. Additionally, the 
prison system can be subject to sudden and significant 
changes to prison procedures and entrants and it was esti-
mated that a minimum of six clusters would be required 
in order to ensure balance, and this would have incurred 
prohibitive costs.
outcome measures
Outcome measure dataii will be collected at approximately 
1 week prerelease and at 1, 3, 6 and 12 months postre-
lease from prison (see table 1). The primary outcome 
point is at 6 months postrelease. The primary outcome 
measure is change in levels of psychological distress as 
indicated by the clinical score of the CORE-OM. This 
is a 34-item scale comprising four domains, namely: 
subjective well-being; depression and anxiety symptoms; 
general, social and close relationship functioning; and 
items concerning risk of harm to self or others. Items are 
rated against how participants felt over the previous week, 
on a 5-point Likert Scale, with eight items reverse scored. 
CORE-OM was chosen as the most appropriate primary 
outcome measure at a consensus meeting following a 
period of pilot testing of a range of outcome measures. In 
particular, the CORE-OM is a reliable and well-validated 
measure,37 was regarded as being quick to administer and 
easy to understand in pilot testing and was considered to 
reflect the ultimate aim of the intervention. The primary 
outcome point is similar to that used in many previous 
prisoner resettlement studies, 3–6 months postrelease 
being widely regarded as a suitable follow-up period as 
the aim of resettlement interventions is to help people 
reintegrate into community life rather than to provide 
long-term support.43 The 12-month follow-up will assess 
whether any benefits brought about by the intervention 
are maintained over a longer time period.
Secondary outcome measures are as follows:
 ► self-reported met need across key outcome domains 
using an adapted version of the Camberwell Assess-
ment of Need-Forensic Version (CAN-FOR),44 in 
terms of the number of met needs and using the Met 
Needs Index as an aggregate measure of met need45;
 ► social outcomes (accommodation, education, employ-
ment and benefits);
 ► drug and alcohol use using and adapted version of the 
Treatment Outcomes Profile (TOP)45;
 ► drug and alcohol dependence using the Leeds 
Dependence Questionnaire (LDQ)46;
 ► service use across health, criminal justice, social care 
and third-sector organisations using an adapted 
version of the CSRI.47 Recent evidence suggests that 
self-reported health service use data is valid in ex-pris-
oner populations48;
 ► perceived helpfulness of services using the adapted 
version of the CSRI;
 ► generic health-related quality of life using the 
EQ-5D-5L questionnaire49;
ii The selection of the primary and secondary outcome measures was 
informed by two consensus exercises and a period of field testing of 
a range of possible measures to establish the psychometric properties 
and acceptability of the measures in this population. This work will be 
presented in a separate article.
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 ► well-being-related quality of life using the ICEpop 
CAPability measure for adults (ICECAP-A) 
questionnaire50;
 ► experience of care using the Brief Inspire 
questionnaire51;
 ► psychological constructs related to desistence using 
the Intermediate Outcomes Measurement Instru-
ment (IOMI)52;
 ► well-being, functioning, psychological symptoms, and 
risk using the subscales of the CORE-OM;
Table 1 Tabulated summary of study schedule
Timepoint
Screening Baseline Allocation Prerelease Postrelease from prison
t0 t1 −1 week t2 +1 month t3 +3 month
3 t4 +6 month t5 +12 month t6
Enrolment
  Eligibility screen X
  Informed consent X
  PHQ-9 X
  GAD-7 X
  PTSD-Screening 
Questionnaire
X
  Historical screen for past 
CMHPs
X
  Allocation* X
Interventions
Intervention 
group
Engager 
intervention
Usual care
Control group Usual care
Assessments
  CORE-OM Questionnaire X X X X X
  CORE-10† X X X X
  Adapted CAN-FOR X X X X
  Adapted CSRI (including 
medication)
X X X X X
  Objective social outcomes 
(eg, housing)
X X X
  TOP X X X X
  Leeds Dependence 
Questionnaire
X X X
  EQ-5D-5L Questionnaire X X X X
  ICECAP-A Questionnaire X X X X
  IOMI X X X
  SAPAS X
  Neurodevelopmental 
Symptoms Rating Scale
X
  Trauma Questionnaire X
  Contact Sheet X X X
  Brief Inspire Questionnaire X X X
  Police National Computer 
Offending Data
X X
Safety monitoring
  Adverse event reporting
*Allocation will be performed using a web-based system provided by the clinical trials unit, usually within 2 days of completing the screening interview.
†CORE-10 will only be completed if it is not possible to complete the CORE-OM Questionnaire.
CAN-FOR, Camberwell Assessment of Need-Forensic Version; CMHP, common mental health problems; CORE-OM, Clinical Outcomes in Routine 
Evaluation-Outcome Measure; CSRI, Client Service Receipt Inventory; GAD-7, Generalised Anxiety Disorder-7; ICECAP-A, ICEpop CAPability measure 
for adults; IOMI, Intermediate Outcomes Measurement Instrument; PHQ-9, Patient Health Questionnaire-9; PTSD, post-traumatic stress disorder; 
SAPAS, Standard Assessment of Personality-Abbreviate Scale; TOP, Treatment Outcomes Profile.
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 ► proven reoffending rates, based on data from the 
Police National Computer.
Due to the nature of the intervention, it will not be 
possible to blind participants or those delivering the 
intervention. Attempts to blind researchers during the 
pilot trial proved challenging and were largely unsuc-
cessful. Therefore, researchers will be aware of which 
group participants are allocated to, and measures will be 
implemented to minimise and measure bias, especially 
for data collection on the primary outcome measure.41 
Specifically, the researchers will use a highly scripted 
interview for the primary outcome measure, reading each 
question to the participants and only deviating from this 
to clarify the meaning of the question if they indicate they 
do not understand the question.
sample size
The sample size is based on the ability to detect a differ-
ence on the primary outcome only and not on the inclu-
sion of baseline measures as covariate. On the CORE-OM, 
5.0 points is the accepted Reliable Change Index in service 
evaluations.53 54 In contrast, 2.5 points is held as the upper 
limit of what would be considered a change compatible 
with equivalence (MBarkham, personal communication, 
2015) in trials comparing two interventions. Other trials 
using the CORE-OM for mental health interventions 
versus treatment as usual or waiting list controls have 
achieved mean between group differences in change 
score of between 3.5 and 7.8.55 56 An SD of 5.6 was found 
in the pilot trial.41 However, larger clinical studies have 
reported larger SDs of approximately 7.5.57
Given the uncertainty, in both SD and the appropriate 
minimally clinically important difference (MCID) for 
the CORE-OM, we calculated sample sizes for different 
scenarios based on the range of values for these two 
parameters (see table 2). This is equivalent to aiming to 
be able to detect a minimum effect size of 0.26 (ie, small 
to medium).
Based on the conservative scenario of an MCID of at least 
3.5 and a common SD of 7.5, we will require CORE-OM 
data on 97 participants in each group at 90% power and 
5% alpha. Using an attrition rate of 30%, 140 participants 
are required per group. Follow-up rates of 63% and 55% 
were achieved in feasibility and pilot work.41 However, 
with learning from the pilot trial and assistance from 
the new Community Rehabilitation Companies (CRCs), 
which now supervise virtually all prison leavers for at least 
1 year, an attrition rate of 30% or less is achievable.
trial data collection
Trial data will be collected from participants at baseline, 
1 week prerelease and at 1, 3, 6 and 12 months postre-
lease. Feasibility and pilot studies highlighted that this 
population often lead chaotic lives and are difficult to 
follow up in the community.41 To address this challenge, 
the research team will make multiple and sustained 
attempts to follow up participants at each time point. 
Community follow-up interviews will be conducted in a 
convenient location for the participants and where appro-
priate in the premises of services (eg, National Probation 
Service or CRC) with which the participant is engaged. 
Participants will be provided with high street shopping 
vouchers compensating them for their time at the 3, 6 
and 12 months postrelease interviews, although this does 
not apply to participants who have returned to prison and 
are interviewed there.
The pilot trial highlighted that some participants can 
be temporarily lost, but subsequently re-emerge (possibly 
engaging with community services or back in prison).41 
Follow-up data collection points will take place within 
broad time-windows. The 1-month follow-up will take 
place between 14 and 60 days postrelease, the 3-month 
follow-up will take place between 61 and 151 days postre-
lease, the 6-month follow-up between 152 and 244 days 
postrelease and the 12-month follow-up between 304 and 
483 days postrelease. Where feasible, follow-up interviews 
will take place as close to 1, 3, 6 and 12 months postre-
lease time points as possible. Furthermore, if a partic-
ipant misses a follow-up interview (eg, at 3 months), 
they will continue to be included in the study until all 
follow-up time-points have lapsed (eg, 483 days postre-
lease), after which point those remaining out of contact 
will be regarded as lost. If the research team is in contact 
with a participant but setting up a face-to-face inter-
view is challenging (or if they have failed to turn up to 
an appointment), researchers will attempt to complete 
the CORE-10iii by telephone. However, even when the 
CORE-10 has been completed, researchers will endeavour 
to follow up participants with a face-to-face interview.
The numbers and reasons for drop-outs and losses to 
follow up will be reported for each arm of the study.
Baseline and 1 week prerelease data collection
Baseline data collection will usually continue immediately 
after the screening interview, although additional sessions 
can be arranged to meet the needs of individual partici-
pants or time constraints within the prison. As outlined in 
table 1, the following data will be collected at this point:
iii The CORE-10 will be used when completing the measure over the 
phone because it is shorter. The 34-item CORE-OM was considered too 
long to complete over the phone with this population of participants.
Table 2 Sample size (for each group) based on different 
values of SD and MCID for the Clinical Outcomes in Routine 
Evaluation-Outcome Measure
SD
5.5 6.5 7.5
Change to be 
detected (MCID)
5.0 26 36 48
4.5 32 44 59
4.0 40 56 74
3.5 52 73 97
At 90% power and two-sided alpha of 5%.
MCID, minimally clinically important difference.
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 ► psychological distress using the CORE-OM;
 ► subjective rating of need across health and social 
domains using an adapted version of the CAN-FOR;
 ► healthcare, criminal justice and other service utilisa-
tion using an adapted version of the CSRI;
 ► objective social outcomes (accommodation, educa-
tion, employment);
 ► drug and alcohol use and dependence using the TOP 
and LDQ;
 ► health-related quality of life using the EQ-5D-5L;
 ► well-being-related quality of life using the ICECAP-A;
 ► IOMI;
 ► Standardised Assessment of Personality-Abbreviate 
Scale;
 ► Neurodevelopmental Symptoms Rating Scale;
 ► experience of traumatic life events using the Trauma 
Questionnaire.
The questions from the standardised measures, 
including the primary outcome measure (CORE-OM), 
will be read out to participants in a precise and consistent 
manner, to minimise bias and overcome any literacy prob-
lems. Questions from the secondary outcome measures 
are incorporated into a specially constructed flexible 
interview, which avoids duplication of subject matter in 
order to reduce disengagement or irritability. Data will be 
recorded in the Baseline Case Report Form.
In addition to the baseline data collection, the 
researcher will complete a contact sheet for each partic-
ipant. This will include contact numbers and addresses 
provided by the participant, as well as a list of services 
that they are likely to be in contact with postrelease. This 
sheet will be completed in collaboration with the partic-
ipant, and they will sign the form to consent that the 
research team can contact them via the relevant services.
The researchers will meet with the participant again 
within the week prior to their release. The service use 
table from the adapted CSRI, to collect information on 
services the participant has seen since the baseline data 
collection, and the Brief Inspire Questionnaire will be 
completed to measure the participant’s experience of 
these services. The researcher will also update contact 
details for the participant.
Information regarding medication prescribed in the 
3 months before prison release, as well as any chronic 
medical conditions or acute conditions in the previous 
12 months, will be collected from the prison healthcare 
records system. Summary data regarding offence history 
and number of previous custodial sentences will also be 
collected from prison records.
Follow-up data collection
At all follow-up meetings, the researcher will remind 
the participant of the information sheet and consent, 
drawing attention to data confidentiality and instances 
of disclosure where the researcher would need to breach 
confidentiality.
At approximately 1 month postrelease, the researcher 
will contact the participant. This follow-up can be 
completed by phone, but preferably face to face to 
support continued engagement. The researcher will read 
aloud to the participant and record responses to the 
CORE-OM. These data will be used in analysis, but the 
main objective of the meeting is sustained engagement 
and planning further contact.
The 3-month, 6-month and 12-month follow-ups will 
take place between 61 and 151 days, 152 and 244 days 
and 304–483 days postrelease, respectively, although 
researchers will endeavour to complete data collection 
close to the 3-month (90 days), 6-month (182 days) and 
12-month (365 days) points. At each time point, partici-
pants will be read the questions from the measures listed 
in table 1.
Economic evaluation
The cost-effectiveness of the intervention to increase 
engagement and access to services and to improve 
mental health outcomes will be assessed. This will be 
compared with service access and support as usual, using 
the economic model developed in the pilot phase, popu-
lated with the trial outcomes and resource use data up to 
12 months postrelease from prison. It will be conducted 
from a public sector perspective, initially with the same 
time horizon as the RCT, and primarily using a cost-conse-
quence approach. Within the cost-consequence approach, 
the estimated incremental costs will be compared with:
 ► The number of people provided with the service/
intervention.
 ► The incremental differences in the main RCT self-re-
ported health outcomes—CORE scores and EQ-5D-5L 
and ICECAP-A social preference weights.
 ► Incremental differences in the number of ex-pris-
oners who: have resettled; are in employment; have 
no proven re-offending; are not homeless.
 ► Estimated lifetime gains in quality-adjusted life years 
(QALYs). Improvements in lifetime gains will be 
linked with short-term gains seen in the trial and will 
be associated with social inclusion outcomes such 
as effective resettlement, increased employment or 
reduced reoffending rates. Sustained improvements 
in these will be modelled based on evidence from 
the literature. We will test the impact of differing the 
duration of the persistence of any short-term gains on 
QALYs (and associated costs) if there is no evidence 
in the literature.
 ► The cost of providing the intervention will be based 
on a combination of process of care data collec-
tion and intervention practitioner care records and 
diaries (bottom-up costing approach) and the total 
costs of service provision (top-down costing). Both 
deterministic and probabilistic sensitivity analysis will 
be conducted to explore uncertainty in the model 
assumptions and parameters, with exploration of key 
sources of structural uncertainty where feasible.
The analyses will be conducted according to current 
guidance from the International Society for Pharma-
coeconomics and Outcomes Research on best practice for 
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conducting trial-based economic evaluation.58 Consistent 
with the analytical approach used in the statistical analysis 
of the effectiveness outcomes of the RCT where possible; 
the cost-effectiveness analysis will be reported in accord-
ance with the Consolidated Health Economic Evaluation 
Reporting Standards.59
Process evaluation
The process evaluation will be conducted in parallel with 
the trial and will adopt a mixed-methods, realist-informed, 
approach.60 During the development and piloting of the 
Engager intervention we produced and refined a theoret-
ically informed, and evidence-based, logic model of the 
ways in which the intervention was understood to work,61 
which we intend to test in the process evaluation. The 
logic model included the core components of the inter-
vention that the practitioners were asked to deliver, the 
key mechanisms of impact (ie, how what the practitioners 
were doing was understood to produce the desired 
outcomes) and the anticipated outcomes.62
Process evaluation specific objectives
a. to determine the degree to which the core compo-
nents of the intervention were delivered and the key 
mechanisms of the intervention occurred;
b. to evaluate the extent to which the core components 
and key mechanisms of the intervention produced 
the intended outcomes;
c. To explore any unintended consequences of deliver-
ing the intervention;
d. to identify aspects of the intervention and delivery 
that could be improved;
e. to identify any aspects of intervention delivery that 
require additional input from practitioner teams 
when the research team is no longer in place;
f. to develop an understanding of how to deliver the 
intervention in real-world settings (training, supervi-
sion, meta-supervision).
data collection
The data collection methods were developed and refined 
for acceptability in the pilot trial Formative Process Eval-
uation and include:
 ► intervention components checklist to measure fidelity 
to the intervention;
 ► semistructured interviews, with a purposively selected 
subsample of participants, some on one occasion and 
some at regular intervals throughout their participa-
tion in the trial;
 ► semistructured interviews with Engager practitioners 
and supervisors throughout the trial;
 ► semistructured interviews with other practitioners and 
team leaders, in other services about their perceptions 
of, and interactions with, the Engager practitioners, 
participants and the intervention;
 ► semistructured interviews with family/partners/
friends of participants receiving the Engager 
intervention;
 ► audio-recordings of practitioner group supervision 
sessions;
 ► audio-recordings of selected practitioner–participant 
interactions;
 ► Engager practitioner records and notes;
 ► quantitative outcome measures, contained within the 
case report form (CRF), and also being used as part of 
the main trial outcomes;
 ► ethnographic field notes recorded by the process eval-
uation researchers.
data analysis
The framework analysis methodology, which we devel-
oped and applied in the Formative Process Evaluation, 
will be used and extended to collate and interrogate the 
process evaluation data.63 The deductive components 
of the framework will be informed by the logic model’s 
key mechanisms of impact, that is, the ways in which we 
understand the intervention to be working. Inductive 
components of the framework will be surfaces as part of 
the analytical process. At the end of this analytical process, 
the logic model of the key mechanisms of impact of the 
intervention will be revised.
The process evaluation researchers will be distinct from 
the researchers collecting outcome measures. They will 
contribute to the qualitative, and therefore more subjec-
tive, data collection and the overall analysis. A ‘critical 
friend’ researcher, external to the outcome measure 
and delivery teams, will facilitate the process evaluation 
researchers’ opportunity to self-reflexively explore how 
their presence affects their data collection and experi-
ences in the field, which may influence their analytical 
processes.62 When the process evaluation data and anal-
ysis can contribute to refining ongoing fidelity to the 
Engager model, it will be fed back directly to the inter-
vention delivery team. When the process evaluation data 
and analysis concerns the outcomes of interest, the data 
will be shared after the trial database has been locked 
down and initial statistical analyses have been carried 
out.
If the main trial does not demonstrate that the inter-
vention is effective, additional analysis of the qualitative 
data will be conducted using thematic methods to explore 
possible explanations for this64 and to glean any addi-
tional learning that may have application to other studies 
with socially marginalised populations and/or those with 
mental health needs.
serious adverse events
Non-serious adverse events will not be recorded. Serious 
adverse events (SAEs) will be recorded and reported. Any 
SAEs deemed to have a causal relationship to trial partici-
pation with be reported to the sponsor within 24 hours of 
the chief investigator being informed.
study timeline
Study start date: 14 January 2016.
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Trial registration date: 4 February  2016.iv
Projected end date for recruitment: 30 September 
2017.
Projected end date for 6-month follow-up data: 31 July 
2018.
Projected initial analysis of primary outcome data: 30 
November 2018.
Projected final report date: 31 October 2019.
Current status: recruiting.
data management and statistical analysis plan
All data will be treated confidentially and stored securely 
and anonymously. CRFs will be checked and signed at the 
research sites by a member of the research team before 
being sent to the PenCTU for double-data entry on to 
a password-protected database. All forms and data will 
be tracked using a web-based trial management system. 
Double-entered data will be compared for discrepancies, 
and discrepant data will be verified using the original 
paper data sheets.
All quantitative data analyses will be conducted and 
reported in accordance with Consolidated Standards 
of Reporting Trials recommendations. We will closely 
monitor the process of data collection during the 
trial providing flow diagrams summarising, by group, 
the numbers approached, recruited, randomised, 
followed up/lost to follow-up and outcome completion.
Primary analyses will be conducted on an intention-
to-treat basis (ie, according to randomised group) and 
compare primary and secondary outcomes at 6-month 
follow-up between randomised groups on those with 
complete data sets. Outcomes will be compared using 
linear-regression-based methods, adjusting for baseline 
outcome scores and stratification variables (eg, investi-
gation centre). Where necessary, outcomes will be trans-
formed to ensure good regression model fit. A secondary 
analysis will compare primary and secondary outcomes 
between groups at all follow-up time points using a 
repeated measures approach. Reasons for missing data 
(including loss to follow-up and participant drop-out) will 
be documented and the baseline characteristics of those 
with and without missing data compared. Using different 
assumptions for missing data, we will undertake sensitivity 
analyses using various imputation models, comparing 
between group results to the completers’ primary anal-
ysis. We shall also explore the possibility of conducting 
secondary per protocol between-group comparisons. If 
possible, this will be based on a predefined minimum 
level of intervention receivership and using complier 
average causal effect analysis methods. The analyst will 
iv The trial was retrospectively registered about 3 weeks after the first 
participant was recruited. The trial was registered on the National Insti-
tute for Health Research Portfolio Database on 15 December 2015, but 
we encountered delays in the information being transferred for trial 
registration. We only became aware of this shortly after we had started 
recruitment and the issue was quickly rectified and the trial was regis-
tered on 4 February 2016.
be blinded to group allocation and the analysis will be 
undertaken using STATA V.14.2.
A detailed statistical analysis plan will be prepared 
before any data analysis is conducted. The statistical anal-
ysis plan will be agreed with the trial steering committee.
trial management and independent committees
Members of the research team directly involved with 
the day-to-day running of the trial will meet fortnightly 
to discuss trial progress, with additional email and tele-
phone exchanges as required. A full trial management 
group including health economists, statisticians, process 
evaluation researchers and a sponsor representative will 
meet quarterly to review trial progress.
The Engager trial steering committee (Chair: Professor 
Pamela Taylor and three other independent members 
including a patient and public involvement representa-
tive) will meet 1–2 times per year to oversee the conduct 
of the trial, safety and ethics. The trial steering committee 
formally agreed that given the social/psychological 
nature of the intervention, only limited safety monitoring 
would be required, and therefore an independent data 
monitoring committee was not required.
Ethics and dissemination
We have obtained National Offender Management 
Service (ref: 2015–283) approval and local Trust gover-
nance approvals for each site (Devon Partnership NHS 
Trust, Dorset Hospital University Foundation NHS Trust 
and Lancashire Care NHS Foundation Trust). The study 
has also been adopted by the National Institute for Health 
Research (NIHR) Clinical Research Network and the 
study sponsor is Devon Partnership NHS Trust.
The trial will be conducted in accordance with the 
ethical principles outlined in the Declaration of Helsinki 
and those consistent with GCP. The trial steering 
committee will ensure adherence to these guidelines. Any 
amendments to the protocol will be submitted for ethical 
approval as appropriate.
Findings will be published in peer-reviewed journals 
and presented at local, national and international confer-
ences to publicise and explain the research to key audi-
ences. A final report will be submitted to NIHR.
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